# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Ovarian cancer

Cancer, Ovarian
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-10 of 605 results.
NeoVax With Nivolumab in Patients With Ovarian Cancer
Status: Not yet recruiting
Last Changed: Jul 18, 2019
First Received: Jul 18, 2019
Disease(s): Ovarian Cancer
Intervention(s): Nivolumab, NeoVax, Core Needle Biopsy
Locations: Dana Farber Cancer Institute, Boston, Massachusetts, United States
Anlotinib for Patients With Platinum Resistant or Refractory Ovarian Cancer
Status: Recruiting
Last Changed: Apr 23, 2019
First Received: Apr 23, 2019
Disease(s): Ovarian Cancer
Intervention(s): Anlotinib
Locations: The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study)
Status: Recruiting
Last Changed: Oct 16, 2019
First Received: May 22, 2018
Disease(s): Ovarian Cancer
Intervention(s): Enoxaparin, Enoxaparin + Rosuvastatin, Thromboprophylaxis
Locations: Massachusetts General Hospital, Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Platino-resistance in Ovarian Cancer
Status: Not yet recruiting
Last Changed: May 17, 2019
First Received: May 17, 2019
Disease(s): Epithelial Ovarian Cancer
Intervention(s): Patients treated with platinum based-chemotherapy
Locations: Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, France
An Observational Study of Combination of Pegylated Liposomal Doxorubicin and Trabectedin in Routine Practice in Patients With Recurrent Partial-platinum Sensitive Ovarian Cancer
Status: Recruiting
Last Changed: Feb 26, 2018
First Received: Feb 26, 2018
Disease(s): Ovarian Cancer
Intervention(s): Trabectedin + PLD
Locations: Almaty oncological center, Almaty, Kazakhstan
Almaty regional oncological dispensary, Almaty, Kazakhstan
Kazakh institute of oncology and radiology, Almaty, Kazakhstan
Kazakh institute of oncology and radiology, Almaty, Kazakhstan
Astana Oncology Center, Astana, Kazakhstan
... and 6 other locations.
Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Nov 06, 2019
First Received: Aug 21, 2018
Disease(s): Ovarian Cancer
Intervention(s): AVB-S6-500, Paclitaxel (Pac), Pegylated liposomal doxorubicin (PLD), Placebo
Locations: Arizona Oncology, Phoenix, Arizona, United States
Kaiser Permanente Oakland, Oakland, California, United States
Stanford University, Palo Alto, California, United States
Kaiser Permanente Roseville, Roseville, California, United States
Kaiser Permanente Sacramento, Sacramento, California, United States
... and 19 other locations.
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer.
Status: Not yet recruiting
Last Changed: May 03, 2019
First Received: May 03, 2019
Disease(s): Ovarian Cancer
Intervention(s): Palbociclib 125mg, Letrozole 2.5mg
Locations: CPO, Porto Alegre, Rio Grande Do Sul, Brazil
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Status: Recruiting
Last Changed: Mar 07, 2019
First Received: Aug 11, 2017
Disease(s): Ovarian Cancer
Intervention(s): Fostamatinib and Paclitaxel
Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients.
Status: Recruiting
Last Changed: Nov 08, 2019
First Received: Nov 09, 2018
Disease(s): Advanced Ovarian Cancer
Intervention(s): Bevacizumab, Durvalumab, Olaparib, Placebo olaparib, Durvalumab placebo, Carboplatin+Paclitaxel
Locations: Research Site, Concord, California, United States
Research Site, Foothill Ranch, California, United States
Research Site, Los Angeles, California, United States
Research Site, Oakland, California, United States
Research Site, Orange, California, United States
... and 203 other locations.
Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer
Status: Recruiting
Last Changed: Sep 03, 2018
First Received: Jul 16, 2018
Disease(s): Ovarian Cancer
Intervention(s): Apatinib
Locations: The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China